🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Breast Cancer
Clinical trial register · Mexico

Breast Cancer Trials in Mexico, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Mexico and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1579 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:45 UTC
1579
Studies in scope
all four open statuses
711
Recruiting now
open to new participants
247
Lead sponsors
across recruiting studies
Top sites
Mexico City 20 Guadalajara 11 Monterrey 10 Oaxaca City 6 México 5
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Hoffmann-La Roche6 AstraZeneca3 Pfizer3 Tolmar Inc.2 Eli Lilly and Company2
Site location
Mexico City20 Guadalajara11 Monterrey10 Oaxaca City6 México5
All 35 locations
Target enrolment
to

Breast Cancer trials in Mexico

37 of 1579 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Mexico
Start
Recruiting
A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer
NCT07225309Breast Cancer, Prostate Cancer, Colorectal Cancer, Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Not applicable
300
Mexico City
2026-05-01
Recruiting
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
NCT07405801Breast Cancer
DrugsInavolisib·Ribociclib·Fulvestrant
Hoffmann-La Roche
Phase 2
80
Distrito Federal, Oaxaca City, Guadalajara
2026-04-07
By invitation
Impact of Supplementation With Synbiotics and Prebiotics on Cognitive Decline Associated With Neoadjuvant Chemotherapy in First-line Patients With Breast Cancer
NCT07465497Chemobrain, Breast Cancer, Inflammatory Disease
Instituto Jalisciense de Cancerologia
Not applicable
80
Zapopan
2026-02-27
Recruiting
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
NCT07368998Breast Cancer
DrugsInavolisib·Fulvestrant
Hoffmann-La Roche
Phase 2
80
Guadalajara, Queretaro Qro, Mexico City
2026-02-18
Recruiting
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
NCT06896474Breast Cancer
Beth Israel Deaconess Medical Center
Not applicable
402
2026-02-04
Recruiting
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
NCT07102381HER2-positive Breast Cancer, Breast Cancer
DrugsZanidatamab·Pertuzumab·Trastuzumab·Docetaxel
Jazz Pharmaceuticals
Phase 2
125
2025-09-24
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965Breast Cancer
DrugsPF-07248144·Exemestane·Everolimus·Fulvestrant
Pfizer
Phase 3
400
Oaxaca City, Mexico City
2025-08-05
Recruiting
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06757634Breast Cancer
DrugsGedatolisib·Ribociclib·Palbociclib·Letrozole
Celcuity Inc
Phase 3
1,180
Aguascalientes, Guadalajara, Mexico City, Monterrey, Morelia
2025-07-24
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693Breast Cancer
DrugsCDK4/6i·Inavolisib·Letrozole
Hoffmann-La Roche
Phase 3
450
Distrito Federal, MexicoCiudad de México, Monterrey, Ciudad de Huajuapan de León, Oaxaca City, Chihuahua City, D.F., Guadalajara
2025-04-09
Recruiting
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT06492616Breast Cancer
DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole
Stemline Therapeutics, Inc.
Phase 3
4,220
2024-09-27
By invitation
Use of Machine Learning Techniques for Serial Assessment of Systemic Inflammatory Markers in Breast Cancer Patients
NCT06447532Breast Cancer
Federal University of São Paulo
Observational
4,500
Mexico City
2024-08-01
Recruiting
BostonGene and Exigent Genomic INsight Study
NCT06272864Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Sarcoma
BostonGene
Observational
400
2024-04-08
Active, closed
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
NCT05458674Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
DrugsTucatinib·Herceptin·Eribulin·Trastuzumab
Criterium, Inc.
Phase 2
17
2024-01-30
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864Breast Cancer
DrugsDatopotamab Deruxtecan·Durvalumab·Nab-paclitaxel·Gemcitabine
AstraZeneca
Phase 3
625
CD Mexico, Guadalajara, Mexico City, México, Tuxtla Gutiérrez
2023-11-23
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Exemestane·Anastrozole·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
510
Guadalajara, Mexico City, Puebla City, San Luis Potosí City, Monterrey, Oaxaca City, Sinaloa
2023-11-16
Active, closed
Physical Activity Intervention for the Improvement of Pain in Young, Hispanic Breast Cancer Survivors
NCT06260332Breast Cancer
New Mexico Cancer Research Alliance
Not applicable
25
2023-10-20
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926Breast Cancer
DrugOvarian Function Suppression
NRG Oncology
Phase 3
3,960
Mexico City
2023-10-18
Active, closed
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
NCT05852691Breast Cancer
DrugsTobemstomig·Nab-paclitaxel·Pembrolizumab
Hoffmann-La Roche
Phase 2
83
Mexico City, Monterrey, Oaxaca City
2023-07-18
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862Breast Cancer
DrugsBupropion·Omeprazole·Alpelisib·Inavolisib
Hoffmann-La Roche
Phase 3
420
Guadalajara, Mexico City, Distrito Federal, Morelia
2023-06-07
By invitation
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
NCT05645536Breast Cancer
DrugsTOL2506·Tamoxifen·Exemestane·Anastrozole
Tolmar Inc.
Phase 3
250
San Juan del Río, Guadalajara, Madero, Mexico City, Veracruz
2022-12-28
Active, closed
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886Breast Cancer
DrugsGedatolisib·Alpelisib·Palbociclib·Fulvestrant
Celcuity Inc
Phase 3
701
Mexico City, Monterrey, Morelia, Nuevo León, Querétaro, Saltillo
2022-12-08
Active, closed
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
NCT05226871Breast Cancer, Head and Neck Cancer
DrugsPalbociclib·Letrozole·Fulvestrant·Cetuximab
Pfizer
Phase 2
35
Monterrey
2022-07-07
Active, closed
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT05374512Breast Cancer
DrugsEribulin·Datopotamab Deruxtecan·Nab-paclitaxel·Capecitabine
AstraZeneca
Phase 3
644
CD Mexico, Guadalajara, Guadalajara Jalisco, Mexico City, México
2022-05-16
Active, closed
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
NCT05262400Breast Cancer, Solid Tumors
DrugsPF-07104091·PF-07220060
Pfizer
Phase 1/2
235
Mexico City, Monterrey, Mérida
2022-03-14
Active, closed
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
NCT04906395Breast Cancer
DrugsTOL2506·Tamoxifen·Exemestane·Anastrozole
Tolmar Inc.
Phase 3
250
Mexico City, San Juan del Río, Veracruz
2021-07-01
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
NCT04873362Breast Cancer
DrugsTrastuzumab emtansine·Herceptin·Tecentriq·Trastuzumab
Hoffmann-La Roche
Phase 3
1,188
La Paz, Distrito Federal, Mexico City, Monterrey, Oaxaca City
2021-05-04
Active, closed
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
NCT04567420Breast Cancer
DrugsPalbociclib·Fulvestrant
Criterium, Inc.
Phase 2
70
2021-02-09
Active, closed
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]
NCT03747120HER2-positive Breast Cancer, Breast Cancer
DrugsPerjeta·Herceptin·Taxol·Pertuzumab
University of Texas Southwestern Medical Center
Phase 2
138
2019-01-25
Active, closed
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
NCT03488693Breast Cancer
Canadian Cancer Trials Group
Phase 3
2,138
2018-10-16
Active, closed
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
NCT03155997Breast Cancer
DrugAbemaciclib
Eli Lilly and Company
Phase 3
5,637
Torreón, Mexico City, Guadalajara, Monterrey, Juchitán de Zaragoza, Culiacán, Toluca, Mérida
2017-07-12
Active, closed
PALbociclib CoLlaborative Adjuvant Study
NCT02513394Breast Cancer
DrugPalbociclib
Alliance Foundation Trials, LLC.
Phase 3
5,796
Monterrey, Toluca, Mexico City
2015-08
Active, closed
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
NCT02246621Breast Cancer
DrugsAnastrozole·Abemaciclib·Letrozole
Eli Lilly and Company
Phase 3
493
Torreón, México, León, Guadalajara, Mexico City, Cuernavaca, Juchitán de Zaragoza, Colinas Del Cimatario
2014-11-06
Active, closed
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
NCT01674140Breast Cancer
DrugsGoserelin Acetate·Leuprolide Acetate·Tamoxifen Citrate·Zoladex
SWOG Cancer Research Network
Phase 3
1,939
2013-09-12
Active, closed
Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery
NCT01349322Breast Cancer
Radiation Therapy Oncology Group
Phase 3
2,354
2011-05-24
Active, closed
Male Breast Cancer: Understanding the Biology for Improved Patient Care
NCT01101425Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Observational
200
México
2010-12
Active, closed
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
NCT00099437Breast Cancer
DrugFulvestrant
AstraZeneca
Phase 3
736
Mexico City, México
2005-02-13
Active, closed
S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
NCT00070564Breast Cancer
DrugsPegfilgrastim·Doxorubicin Hydrochloride·Cyclophosphamide·Paclitaxel
SWOG Cancer Research Network
Phase 3
3,294
2003-11
Rows per page Showing 1–37 of 37
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Mexican investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-mexico/condition/breast-cancer

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Mexico and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,579 studies in total at the last sync on 26 Sep 2026, 19:45 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 37 of those studies listing the condition Breast Cancer.

How many Breast Cancer trials are recruiting in Mexico?

13 of the 37 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:45 UTC sync. A further 0 have not yet opened recruitment, 21 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Breast Cancer), 37 studies
PhaseStudiesRecruitingShare
Phase 321756.8%
Phase 28321.6%
Not applicable4210.8%
Observational318.1%
Phase 1/2102.7%

Most active sponsors

Lead sponsors with the most studies (Breast Cancer)
Lead sponsorStudiesRecruiting
Hoffmann-La Roche64
AstraZeneca31
Pfizer31
Celcuity Inc21
Criterium, Inc.20
Eli Lilly and Company20
SWOG Cancer Research Network20
Tolmar Inc.20
Alliance Foundation Trials, LLC.10
Beth Israel Deaconess Medical Center11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.